Instead, take the following steps: Monitor and document your symptoms: Keep a menstrual diary noting cycle length, flow heaviness, duration, and any associated symptoms (pain, mood changes) Record the timing of changes in relation to starting Rybelsus or dose adjustments Note any other new symptoms or medications Contact your GP or diabetes team if you experience: Periods that are significantly heavier than usual or last longer than 7 days Very heavy bleeding with symptoms of dizziness, fatigue or shortness of breath (seek urgent care) Bleeding between periods (intermenstrual bleeding) or after intercourse, especially if persistent Absence of periods for more than 3 months (if previously regular) Severe pelvic pain or other concerning symptoms Positive pregnancy test (Rybelsus should be discontinued immediately if pregnancy occurs) Your healthcare provider may: Conduct a clinical assessment including gynaecological history Perform a pregnancy test if appropriate Arrange initial blood tests such as thyroid function and prolactin Consider additional hormone tests (FSH, LH, oestradiol) based on clinical findings Consider pelvic ultrasound if structural abnormalities are suspected Refer to gynaecology if appropriate For women of childbearing potential, it is crucial to maintain reliable contraception whilst taking Rybelsus
That pump that leaves you pushing for longer and harder than you ever have before
Systemic Implications If an 85 mg/day human protocol were sustained over 8 weeks to match the murine intranasal timeline, it would cross into a biochemically hazardous profile: Hepatic Accumulation: The primary adverse effect of chronic copper toxicity is hepatotoxicity
A 2024 Scandinavian study of nearly 150,000 people found no meaningful increase in thyroid cancer risk among users of GLP-1 drugs (the class Mounjaro belongs to)
Contact your doctor right away if you experience unusual symptoms
